For Q1 FY2026 (ended March 31, 2026), Kura Oncology reported revenue of $18.3 million, up 29.5% year-over-year. Net loss was $73.3 million, a 27.7% increase from the prior year, with diluted EPS of -$0.83. Operating loss widened to $78.8 million. Cash stood at $39.1 million, equity at $107.9 million, and long-term debt at $9.7 million.
•Revenue grew 29.5% YoY to $18.3 million.
•Net loss increased 27.7% to $73.3 million; diluted EPS was -$0.83.
•Operating loss expanded 21.8% to $78.8 million.
•Cash and equivalents totaled $39.1 million; long-term debt was $9.7 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor.
Its portfolio also includes Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications, and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of cancer. Its lead product candidate is KOMZIFTI (ziftomenib), a potent, selective, reversible, and oral small molecule menin inhibitor. The company also has a portfolio that includes Darlifarnib, which is being evaluated in a Phase 1 first-in-human FIT-001 trial with multiple cohorts in combination with other targeted therapies for large solid tumor indications. Additionally, Kura is developing KO-7246, a next-generation menin inhibitor intended for use in diabetes and cardiometabolic disorders, as well as additional next-generation menin inhibitors for combination therapies in solid tumors. The company operates in the biotechnology industry within the healthcare sector.
Where is Kura Oncology (KURA) listed and what currency is used?
Kura Oncology, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol KURA. The company's financial reporting and stock trading are conducted in US Dollars (USD). As a US-based company, its shares are traded on this major American stock exchange, providing liquidity and visibility to investors. The listing on NasdaqGS indicates that the company meets stringent listing requirements, including corporate governance and financial standards.
What sector and industry does Kura Oncology belong to?
Kura Oncology operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on developing novel therapies for cancer treatment. The biotechnology industry involves using biological processes and organisms to develop drugs and medical technologies. Kura's work in developing small molecule inhibitors, such as menin inhibitors, places it at the forefront of targeted cancer therapies. The company's research and development efforts are aimed at addressing unmet medical needs in oncology, leveraging its expertise in precision medicine.
Where is Kura Oncology headquartered and what markets does it serve?
Kura Oncology is headquartered in San Diego, California, United States. As a US-based company, it primarily serves the American market, but its clinical trials and potential future products aim to address global cancer treatment needs. The company's location in San Diego places it within a major biotech hub, providing access to talent, research institutions, and collaboration opportunities. While its current focus is on developing therapies for cancer, its pipeline includes candidates for diabetes and cardiometabolic disorders, indicating potential expansion into broader therapeutic areas.
What are the key products in Kura Oncology's pipeline?
Kura Oncology's pipeline includes several key product candidates. The most advanced is KOMZIFTI (ziftomenib), a potent, selective, reversible, and oral small molecule menin inhibitor for cancer treatment. Another candidate is Darlifarnib, currently in a Phase 1 first-in-human FIT-001 trial that includes multiple cohorts evaluating it in combination with other targeted therapies for large solid tumor indications. The company is also developing KO-7246, a next-generation menin inhibitor for diabetes and cardiometabolic disorders, along with additional next-generation menin inhibitors for use in combination therapies in solid tumors. These products reflect Kura's focus on targeted therapies and precision medicine.